Lilly Presents Initial Clinical Data for Sofe-M in Ovarian Cancer

Eli Lilly presented the first clinical data for Sofetabart mipitecan (Sofe-M) in platinum-sensitive ovarian cancer at the ESMO 2026 congress. The drug, combined with bevacizumab, showed a confirmed objective response rate of 79% and a disease control rate of 100%.

AI-written summary of 2 sources; every verified point is backed by a verbatim quote. How Iyan works

• The drug showed similar activity across different levels of FRα expression, according to the company.

  «with similar activity observed across FRα expression»

  AOL
• The drug is advancing toward Phase 3 studies following Phase 1 results in ovarian cancer.

  «as the drug advances toward Phase 3 studies»

  Blockonomi
• The company's shares fell 2.54% despite the drug's positive Phase 1 results.

  «Eli Lilly (LLY) stock fell 2.54% despite Sofe-M posting a 79.3% response rate»

  Blockonomi

Iyan — See it for yourself. What changed in your world today, why it matters, and how we know.
How it works • Privacy • Terms